publication venue for Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients.. 12:2461963. 2025 Improved Overall Survival in Dual Compared to Single Immune Checkpoint Inhibitors in BRAF V600-Negative Advanced Melanoma. 9:MMT60. 2022
